After a 9-week course of Batten-1* with the maximum dose of 600 mg/day, the first results of the Phase I/II trial enrolling six patients with juvenile Batten disease (CLN3) aged 17 and over showed good patient safety and tolerability, and a pharmacokinetic profile in line with expectations.

To read more about the announcement go to https://www.accesswire.com/.../New-Advance-to-the...

Further information about the trial is available on https://clinicaltrials.gov/ct2/show/NCT05174039.

* Batten-1 is a novel and exclusive proprietary drug containing the active ingredient miglustat.